143 related articles for article (PubMed ID: 32414298)
1. Adjusting for adherence in randomized trials when adherence is measured as a continuous variable: An application to the Lipid Research Clinics Coronary Primary Prevention Trial.
Wanis KN; Madenci AL; Hernán MA; Murray EJ
Clin Trials; 2020 Oct; 17(5):570-575. PubMed ID: 32414298
[TBL] [Abstract][Full Text] [Related]
2. Adherence adjustment in the Coronary Drug Project: A call for better per-protocol effect estimates in randomized trials.
Murray EJ; Hernán MA
Clin Trials; 2016 Aug; 13(4):372-8. PubMed ID: 26951361
[TBL] [Abstract][Full Text] [Related]
3. Interval-cohort designs and bias in the estimation of per-protocol effects: a simulation study.
Young JG; Vatsa R; Murray EJ; Hernán MA
Trials; 2019 Sep; 20(1):552. PubMed ID: 31488202
[TBL] [Abstract][Full Text] [Related]
4. The Lipid Research Clinics Coronary Primary Prevention Trial. Results of 6 years of post-trial follow-up. The Lipid Research Clinics Investigators.
Arch Intern Med; 1992 Jul; 152(7):1399-410. PubMed ID: 1627020
[TBL] [Abstract][Full Text] [Related]
5. Adherence-adjustment in placebo-controlled randomized trials: An application to the candesartan in heart failure randomized trial.
Murray EJ; Claggett BL; Granger B; Solomon SD; Hernán MA
Contemp Clin Trials; 2020 Mar; 90():105937. PubMed ID: 31982649
[TBL] [Abstract][Full Text] [Related]
6. Improved adherence adjustment in the Coronary Drug Project.
Murray EJ; Hernán MA
Trials; 2018 Mar; 19(1):158. PubMed ID: 29506561
[TBL] [Abstract][Full Text] [Related]
7. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.
JAMA; 1984 Jan; 251(3):351-64. PubMed ID: 6361299
[TBL] [Abstract][Full Text] [Related]
8. Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.
Kubo Y; Sterling LR; Parfrey PS; Gill K; Mahaffey KW; Gioni I; Trotman ML; Dehmel B; Chertow GM
Pharm Stat; 2015; 14(3):242-51. PubMed ID: 25851955
[TBL] [Abstract][Full Text] [Related]
9. Assessing efficacy in non-inferiority trials with non-adherence to interventions: Are intention-to-treat and per-protocol analyses fit for purpose?
Dodd M; Carpenter J; Thompson JA; Williamson E; Fielding K; Elbourne D
Stat Med; 2024 May; 43(12):2314-2331. PubMed ID: 38561927
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial.
Schaefer EJ; Lamon-Fava S; Jenner JL; McNamara JR; Ordovas JM; Davis CE; Abolafia JM; Lippel K; Levy RI
JAMA; 1994 Apr; 271(13):999-1003. PubMed ID: 8139085
[TBL] [Abstract][Full Text] [Related]
11. Beyond the intention-to-treat in comparative effectiveness research.
Hernán MA; Hernández-Díaz S
Clin Trials; 2012 Feb; 9(1):48-55. PubMed ID: 21948059
[TBL] [Abstract][Full Text] [Related]
12. The Lipid Research Clinics Coronary Primary Prevention Trial.
Rifkind BM
Drugs; 1986; 31 Suppl 1():53-60. PubMed ID: 3720571
[TBL] [Abstract][Full Text] [Related]
13. [Lipid intervention and coronary heart disease in men less than 56 years of age. The Coronary Intervention Study: CIS].
Rensing UF; Bestehorn HP; Roskamm H; Petersen J; Betz P; Spinder M; Benesch L; Schemeitat K; Blümchen G; Claus J; Wieland H; Böcker JF; Neiss A; Stiepel E; Mathes P; Kappenberger L; Braunagel K; Peters K; Meister G; Samek L; Schuon J; Leimenstoll B; Kiefer H
Z Kardiol; 1999 Apr; 88(4):270-82. PubMed ID: 10408031
[TBL] [Abstract][Full Text] [Related]
14. Commentary on the published results of the Lipid Research Clinics Coronary Primary Prevention Trial.
Kronmal RA
JAMA; 1985 Apr; 253(14):2091-3. PubMed ID: 3883022
[No Abstract] [Full Text] [Related]
15. Selections from current literature: the fight over fat: is pharmacological lipid lowering useful for coronary primary prevention?
Green L
Fam Pract; 1997 Oct; 14(5):411-5. PubMed ID: 9472378
[TBL] [Abstract][Full Text] [Related]
16. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial.
Gordon DJ; Knoke J; Probstfield JL; Superko R; Tyroler HA
Circulation; 1986 Dec; 74(6):1217-25. PubMed ID: 3536151
[TBL] [Abstract][Full Text] [Related]
17. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial.
Pflugfelder PW; Huff M; Oskalns R; Rudas L; Kostuk WJ
J Heart Lung Transplant; 1995; 14(4):613-22. PubMed ID: 7578166
[TBL] [Abstract][Full Text] [Related]
18. Pravastatin alone and in combination with low-dose cholestyramine in patients with primary hypercholesterolemia and coronary artery disease.
Ito MK; Shabetai R
Am J Cardiol; 1997 Sep; 80(6):799-802. PubMed ID: 9315597
[TBL] [Abstract][Full Text] [Related]
19. Adjustment for treatment changes in epilepsy trials: A comparison of causal methods for time-to-event outcomes.
Dodd S; Williamson P; White IR
Stat Methods Med Res; 2019 Mar; 28(3):717-733. PubMed ID: 29117780
[TBL] [Abstract][Full Text] [Related]
20. Lipid Research Clinics Coronary Primary Prevention Trial: results and implications.
Rifkind BM
Am J Cardiol; 1984 Aug; 54(5):30C-34C. PubMed ID: 6382999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
